Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder

Major depressive disorder (MDD) is a leading cause of disability worldwide, yet current treatment strategies remain limited in their mechanistic diversity. Recent evidence has highlighted a promising novel pharmaceutical target—the KCNQ-type potassium channel—for the treatment of depressive disorder...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Aaron, Costi, Sara, Morris, Laurel S., Van Dam, Nicholas T., Kautz, Marin, Whitton, Alexis E., Friedman, Allyson K., Collins, Katherine A., Ahle, Gabriella, Chadha, Nisha, Do, Brian, Pizzagalli, Diego A., Iosifescu, Dan V., Nestler, Eric J., Han, Ming-Hu, Murrough, James W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494706/
https://www.ncbi.nlm.nih.gov/pubmed/30385872
http://dx.doi.org/10.1038/s41380-018-0283-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494706/
https://www.ncbi.nlm.nih.gov/pubmed/30385872
http://dx.doi.org/10.1038/s41380-018-0283-2

Ejemplares similares